CVTX CV Therapeutics (MM)

- Data Presented as Hotline Session at 2005 European Society of Cardiology (ESC) Meeting - STOCKHOLM, Sweden, Sept. 4 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (NASDAQ:CVTX) announced today that perindopril improved cardiac function, including left ventricular (LV) remodeling, in elderly patients following a heart attack, based on data presented today from the PREAMI (Perindopril and Remodeling in Elderly with Acute Myocardial Infarction) study during a Hotline session of the ESC Congress 2005 in Stockholm, Sweden. In the study, perindopril reduced the primary endpoint, a combination of death, hospitalization for heart failure and LV remodeling, by 38 percent (p